Core Insights - The year 2025 marks a "watershed" moment for China's flow cytometry market, driven by geopolitical uncertainties and a shift towards "deep localization" as a survival necessity for companies [1][2] Market Overview - The total bid amount for flow cytometers in 2025 reached 641,297,934 yuan, with a total of 486 units awarded [3] - BD retained the top position in bid amounts, while Beckman Coulter surpassed BD in bid quantity, indicating a significant market reshuffle influenced by geopolitical factors and localization strategies [2][5] Competitive Landscape - Beckman Coulter emerged as the top bidder in terms of quantity, while BD maintained the highest bid amount, with the gap in bid amounts between the two companies narrowing from nearly 20% in 2024 to less than 3% in 2025 [10] - The top three companies accounted for over 60% of the total bid amount, while the top ten accounted for over 90% [3][5] Product Performance - Beckman Coulter dominated the top ten bid models, securing the first, second, fifth, and sixth positions with models such as DxFLEX and CytoFLEX [7][9] - The highest bid price for a flow cytometer was 11,486,000 yuan for Standard BioTool's Hyperion XTi, while the lowest was under 50,000 yuan for a model from Rescale [11] User Demand and Market Trends - Hospitals accounted for approximately 48.83% of the bid amount and 48.03% of the bid quantity, with a notable increase in demand from disease control centers, particularly due to a large order from the Xinjiang CDC [15] - The market is witnessing a shift towards lower-tier cities, with significant growth expected in the southwest and central regions of China [20] Regional Insights - The top regions for flow cytometer bids in 2025 included Guangdong (11.9%), Beijing (10.8%), and Shanghai (9.9%), with increasing demand in the southwest and central regions [17][19]

Core Insights - In 2025, a total of 10 flow cytometers received NMPA certification, with 9 being domestic brands, indicating a trend towards high-end, intelligent, and multi-parameter technology that supports clinical precision medicine [1][30]. Group 1: Industry Overview - Flow cytometry, developed in the 1970s, has evolved from basic research to clinical applications in disease diagnosis and treatment monitoring, with the first flow cytometer introduced in China in the early 1980s [2]. - Flow cytometers can measure cell size, internal particle characteristics, and detect surface and cytoplasmic antigens, as well as DNA and RNA content, allowing for rapid analysis of large cell populations [2]. Group 2: Certification and Product Highlights - In 2025, 10 flow cytometers were approved, including 9 domestic brands and 1 imported brand, with notable models such as Cl inStel lar AX from Chenglang Bio, which received certification in December [3][6]. - The Cl inStel lar AX is a high-end spectral flow cytometer that breaks the monopoly of imported brands in the high-end clinical field, providing cost-effective solutions for domestic medical institutions [6][30]. - The BioCy teX from Zhongsheng Medical is the first domestic 4-laser 21-color flow cytometer, marking a significant breakthrough in high-end flow cytometry capabilities [15][30]. Group 3: Technological Advancements - Prism Tech has achieved breakthroughs in PMT and APD detector technologies, creating a dual-platform system that enhances the technical breadth and application depth of domestic flow cytometers [7][30]. - Automation and intelligence upgrades are evident in devices like the Khroma series from Meiruite and EasyCell Plus from Weigong Technology, which feature high-throughput automatic sample loading systems [10][19][30]. Group 4: Market Trends and Future Outlook - The rapid increase in domestic brand certifications indicates a shift towards domestic alternatives and internationalization, with Zhongsheng Medical's BioCy te gaining registration in Indonesia, marking the beginning of overseas expansion for domestic manufacturers [31]. - The flow cytometry market is moving towards automation, intelligence, and multi-dimensional development, expanding applications from hematology to oncology, cell therapy, and infectious immunity [31].

一间不足10平方米的细胞存储室，3个零下196摄氏度的液氮罐、1台零下80摄氏度的冷柜里，藏着企业出海的 新密码。它像一个细胞母体，源源不断地为河南凯普瑞生物技术有限公司（以下简称"凯普瑞生物"）十万级 GMP净化车间裂变能量，"小细胞、大能量"让这家高新技术企业在免疫学领域的研发和转化具象化了。 近日，记者走进位于郑州高新区的凯普瑞生物十万级GMP净化车间。在洁净明亮的产线上，工作人员正有序 封装流式抗体试剂。完成入库的产品被整齐摆放在恒温冷柜中，即将发往国内外市场。 这家生物医药企业专注于杂交瘤细胞株、流式细胞抗体试剂、流式细胞仪及相关产品的研发、生产及技术服 务，已自主开发320余种杂交瘤细胞株，累计推出2200余种流式诊断产品，可覆盖血液、肿瘤、免疫、感染、 细胞治疗等95%以上的临床诊断检测。其产品远销亚洲、美洲、欧洲、大洋洲，以"美国研发+中国智造+全球 营销"的独特运营模式，成为全产业链布局的流式诊断领域领军企业。 "流式诊断就像给细胞做'精准解码'，核心技术'卡脖子'，出海就无从谈起。"在凯普瑞生物研发车间，技术负 责人祁梦丹正在验证新生产的抗体。"这些细胞株和抗体是我们的立身之本，每一款新产 ...

Core Viewpoint - Wuhan University plans to procure instruments and equipment in the fields of life health, basic research, drug screening, and geospatial studies from March to May 2026, with a total budget of approximately 290.898 million yuan [1][2]. Procurement Summary - The total budget for the procurement is set at 290.898 million yuan, with the expected procurement period from March to May 2026 [2]. - The planned instruments include: - Stable isotope ratio mass spectrometer - Flow cytometer - PCR instrument - Cryo-confocal optical correlation microscope - Ultracentrifuge - High-throughput rapid protein liquid chromatography system - Central double-stage pure water system - Field emission scanning electron microscope - High-resolution inverted fluorescence microscope [2][3]. Detailed Procurement List - The procurement list includes various advanced instruments with specific budget allocations, such as: - High-content screening system: 83.784 million yuan, scheduled for May 2026 - Stable isotope ratio mass spectrometer (EA-IRMS): budget not specified - Digital interactive microscope systems: budget not specified - High-throughput quantitative PCR instrument: budget not specified - Ultracentrifuge: budget not specified - Laser confocal microscope: budget not specified - Multi-functional enzyme label instrument: budget not specified - High-resolution laser scanning confocal microscope: budget not specified [2][3][5]. Additional Equipment for Geospatial Studies - The procurement also includes equipment for geospatial studies, such as: - Quartz spring relative gravity meter: 2 sets, budget of 370.4 million yuan - Geomagnetic observation system: 1 set - High-density resistivity system: 1 set - Polarizing microscope: 6 sets [5][6].

Core Insights - The article discusses the 2025 provincial-level warning directory for newly purchased large scientific research facilities and instruments, highlighting the proactive measures taken by Shandong, Henan, and Guangxi provinces to avoid redundant purchases and enhance the efficiency of scientific instruments [1][2]. Summary by Sections Overview of the Warning Directory - The warning directory serves as an important basis for evaluating the purchase of large scientific research facilities and instruments valued at 500,000 yuan or more using provincial financial allocations [2][3]. Provincial Focus Areas - Each province has tailored its warning directory based on its specific scientific instrument layout and usage. For instance: - Henan Province lists seven types of instruments, including flow cytometers, PCR instruments, and laser confocal fluorescence microscopes [3]. - Shandong Province focuses on nine types, such as X-ray diffractometers and gas chromatographs [3]. - Guangxi Province emphasizes five types, including PCR instruments and DNA sequencers [7]. Detailed Instrument Distribution - The article provides detailed distribution data for various instruments across cities within the provinces: - In Henan, for example, there are 61 flow cytometers in Zhengzhou and 45 PCR instruments also in Zhengzhou [6]. - In Shandong, 56 X-ray diffractometers are located in Jinan, and 99 liquid chromatographs are also in Jinan [8][9]. Implications for Research Efficiency - The establishment of these directories signals a commitment to improving the utilization of scientific instruments and reducing financial waste associated with idle equipment [2][3].

Core Viewpoint - The article discusses the release of the "2025 Shandong Province Key Focus Directory for Newly Purchased Large Scientific Research Instruments," which includes nine categories of instruments aimed at optimizing resource allocation and enhancing the efficiency of scientific research in the province [1][2]. Summary by Relevant Sections Overview of the Directory - The directory includes nine types of scientific research instruments such as X-ray diffractometers, mass spectrometers, and flow cytometers, which are essential for various research applications [2]. - The directory serves as a critical reference for provincial universities and research institutions when purchasing large scientific instruments valued at 500,000 yuan or more [2]. Instrument Categories and Regional Distribution - The nine categories of instruments listed in the directory are: 1. X-ray diffractometer 2. Inductively Coupled Plasma Emission Spectrometer 3. Inductively Coupled Plasma Mass Spectrometer 4. Gas Chromatograph 5. Liquid Chromatograph 6. Flow Cytometer 7. Laser Confocal Microscope 8. Ultracentrifuge 9. Fluorescent Quantitative PCR Instrument [2][3]. - The distribution of these instruments across different cities in Shandong Province is as follows: - X-ray diffractometer: Jinan (56), Qingdao (36), Yantai (7), Dongying (6) [3]. - Inductively Coupled Plasma Emission Spectrometer: Jinan (27), Qingdao (25), Linyi (13), Binzhou (13) [3]. - Inductively Coupled Plasma Mass Spectrometer: Qingdao (44), Jinan (43), Weifang (20), Yantai (13) [3]. - Gas Chromatograph: Qingdao (22), Jinan (17), Yantai (11), Binzhou (8) [3]. - Liquid Chromatograph: Jinan (99), Qingdao (65), Yantai (41), Weihai (23) [3]. - Flow Cytometer: Jinan (109), Qingdao (36), Yantai (21), Jining (8) [3]. - Laser Confocal Microscope: Jinan (71), Qingdao (30), Tai'an (13), Jining (9) [3]. - Ultracentrifuge: Jinan (44), Qingdao (12), Tai'an (10), Yantai (9) [3]. - Fluorescent Quantitative PCR Instrument: Jinan (35), Tai'an (25), Qingdao (8), Binzhou (5) [3]. Implementation and Guidelines - Relevant institutions are required to conduct evaluations before purchasing new large scientific instruments, ensuring adherence to the directory and preventing unreasonable growth in the number of instruments listed [2]. - The initiative aims to enhance the utilization efficiency and sharing level of large scientific research instruments in Shandong Province [2].

Core Insights - The flow cytometer industry in China is projected to reach a market size of approximately 3.599 billion yuan in 2024, reflecting a year-on-year growth of 19.21% [1][9] - The industry is achieving systematic breakthroughs along three main paths: expanding detection limits, enhancing analytical dimensions, and integrating functional platforms [1][9] Industry Overview - Flow cytometers utilize lasers to detect scattered light and fluorescence signals from cells or particles in a high-speed flow state, enabling rapid multi-parameter analysis, sorting, and quantitative characterization [2] - The core principle involves hydrodynamic focusing technology that allows cells to pass through the laser detection area in a single file, capturing forward scatter (indicating cell size), side scatter (indicating internal complexity), and fluorescence signals [2] Industry Development History - The flow cytometer industry in China has evolved over 40 years, starting with the introduction of the first FACS III in 1981, leading to significant milestones in domestic production and technology breakthroughs from 2013 onwards [4] - Key advancements include the introduction of the first clinical spectral flow cytometer and the first flow mass spectrometer with IVD registration, marking significant progress in high-end equipment [4] Market Size - The flow cytometer market is experiencing a shift from laboratory to clinical applications, with a notable increase in market size and technological advancements [9] - Noteworthy innovations include the development of nano-flow technology by Fuliu Biotechnology, which extends detection limits to 24nm, and the NL-CLC spectral flow cytometer by Xiatai Biotechnology, the first clinical-approved full-spectrum product in China [9] Key Companies - Major players in the flow cytometer market include Mindray Medical, which has integrated instruments, reagents, and software into a comprehensive platform, and Fuliu Biotechnology, a leader in nano-flow technology [10][11] - Mindray's revenue for the first three quarters of 2025 was 25.834 billion yuan, a decrease of 12.38% year-on-year, with a net profit of 7.570 billion yuan, down 28.83% [11] Industry Trends - The industry is witnessing accelerated technological iteration, with a focus on high-end and intelligent advancements, including the integration of AI for data analysis and high-throughput sorting [12] - Applications are expanding beyond clinical and research fields into broader industrial and public health areas, such as environmental monitoring and food safety [13] - The domestic production process is accelerating, driven by supply chain security and the need for local alternatives, reshaping the competitive landscape [14]

Core Viewpoint - Anhui University of Traditional Chinese Medicine has announced multiple government procurement intentions for laboratory equipment, with a total budget of 82.61 million yuan, covering 16 items of equipment expected to be procured between June 2025 and January 2026 [1][2]. Procurement Summary - The procurement includes various advanced instruments such as isothermal titration calorimeters, bioactivity analyzers, nanoparticle tracking analysis instruments, high-performance liquid chromatographs, nuclear magnetic resonance spectrometers, and X-ray diffractometers [2][4]. - The total budget for the procurement is 82.61 million yuan, indicating significant investment in laboratory capabilities [2][4]. - The procurement is aimed at enhancing the experimental teaching and research capabilities of the university, particularly in the fields of traditional Chinese medicine and related biomedical research [4][6]. Detailed Procurement Items - The procurement list includes: - Isothermal titration calorimeter - Bioactivity analyzer - Nanoparticle tracking analysis instrument - High-performance liquid chromatograph - Nuclear magnetic resonance spectrometer - X-ray diffractometer - Other essential laboratory equipment [2][4][5]. - Specific projects include: - A total of 89 sets of teaching instruments for the pharmacy college, focusing on high-frequency usage in experimental courses [4]. - A budget of 368,000 yuan for basic experimental equipment to support analysis and molecular biology platforms [6]. - A high-resolution mass spectrometer for drug impurity identification and analysis of traditional Chinese medicine components [6][7]. Service and Quality Requirements - The procurement requires that all equipment must meet national standards, be of qualified quality, and have a warranty period of no less than two years, with a supply and installation period of 90 days [6][7]. - After-sales service must include at least 2-3 visits per year to ensure normal operation and supply of spare parts [5][6].

Core Viewpoint - Westlake Laboratory, established in July 2020, focuses on breakthroughs in life sciences and biomedicine, particularly in aging-related diseases and cancer research [3]. Group 1: Recruitment Information - Westlake Laboratory is publicly recruiting for multiple tenure-track positions across all academic levels, encouraging scholars with expertise in aging and neurodegenerative fields to apply [5]. - Applicants must hold a PhD or equivalent degree, have an outstanding research record, innovative future research plans, and a commitment to teaching excellence and diversity [5]. Group 2: Benefits and Resources - Successful applicants will receive competitive salaries and benefits, substantial startup funding, modern laboratory space, and access to advanced core facilities, including cryo-electron microscopy and mass spectrometry [6]. - The laboratory has developed a supportive and vibrant research community aimed at exploring fundamental biological and disease-related questions, developing advanced technologies for human health, and nurturing the next generation of research leaders [6]. Group 3: Application Requirements - Applicants are required to submit a cover letter outlining their research goals, significant achievements, and relevant experience [8]. - A complete academic CV and a research summary statement (maximum 1 page) along with a research proposal (maximum 3 pages) must also be included [9][10]. - Candidates for the assistant professor position must arrange for three referees to send recommendation letters directly [11].

Core Viewpoint - The localization of foreign instrument companies in China is accelerating, driven by government policies such as a 20% price discount for eligible products and new regulations from the State Council, leading to a significant transformation in the competitive landscape of the instrument market [2][3]. Group 1: Localization Models - 2025 is identified as the "Year of Localization" for foreign instrument companies, with four primary localization models emerging: 1. **Production Base Localization**: Companies are establishing manufacturing bases in China to enhance responsiveness to market demands and reduce production costs [3][4]. 2. **Innovation and R&D Localization**: Some firms are focusing on local innovation by setting up R&D centers in China to better understand market needs and develop tailored products [5]. 3. **Supply Chain and Cooperation Localization**: Companies are building local supply chains and collaborating with domestic suppliers and research institutions to enhance their integration into the Chinese market [6]. 4. **Key Product Localization Breakthroughs**: Certain companies are achieving breakthroughs in local production of critical medical devices, thereby strengthening their brand presence and market share in China [7]. Group 2: Reshaping Market Competition - The accelerated localization process is reshaping the competitive landscape of China's instrument market, characterized by increased concentration and differentiated competition. Foreign companies maintain dominance in high-end markets due to their technological advantages and brand equity, while local firms are adopting differentiated strategies to compete effectively [8][9]. - Local companies are leveraging cost control, rapid response mechanisms, and flexible customization services to create a niche in the mid-to-low-end market, gradually breaking the monopoly of foreign firms in specific segments [9][10]. - The "Belt and Road" initiative is enabling local companies to leverage cost advantages and geographical familiarity to establish a collaborative competitive landscape with foreign firms in emerging markets, further optimizing the domestic market structure [10]. Group 3: Opportunities and Challenges - The new competitive landscape presents significant opportunities for local companies to upgrade and transform, driven by national policies promoting self-sufficiency in high-end instruments and the growth of downstream industries like smart manufacturing and biomedicine [11]. - However, foreign brands still dominate high-end markets due to their patent barriers and established service ecosystems, posing challenges for local firms in terms of technology gaps and service capabilities [12][13]. - Local companies need to adopt differentiated strategies to navigate this complex environment, focusing on core technology breakthroughs and enhancing their operational efficiency by learning from foreign firms [14].